Publications by authors named "Robert Conry"

Claim this Profile
P
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.
Antoni Ribas, Mohammed M Milhem, Christopher J Hoimes, Asim Amin, Christopher D Lao, Robert M Conry

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Michael B Atkins, Sandra J Lee, Bartosz Chmielowski, Ahmad A Tarhini, Gary I Cohen, Robert M Conry

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
Kenneth F Grossmann, Megan Othus, Sapna P Patel, Ahmad A Tarhini, Vernon K Sondak, Robert M Conry

Cancer Discov· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.
Mansoor N Saleh, Manish R Patel, Todd M Bauer, Sanjay Goel, Gerald S Falchook, Robert M Conry

Clin Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.
Mansoor N Saleh, Manish R Patel, Todd M Bauer, Sanjay Goel, Gerald S Falchook, Robert M Conry

Clin Cancer Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
Alain P Algazi, Megan Othus, Adil I Daud, Roger S Lo, Janice M Mehnert, Robert Conry

Nat Med· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition.
Roman L Travis, Samuel R Marcrom, Matthew H Brown, Mayank P Patel, James M Markert, Robert Conry

Adv Radiat Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pimasertib Versus Dacarbazine in Patients With Unresectable -Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover.
Celeste Lebbé, Caroline Dutriaux, Thierry Lesimple, Willem Kruit, Joseph Kerger, Robert Conry

Cancers (Basel)· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of Immune Checkpoint Blockade-Induced Myocarditis Over 2 Years.
Timothy G Norwood, Carrie A Lenneman, Brian C Westbrook, Silvio H Litovsky, Svetlana B McKee, Robert M Conry

JACC Case Rep· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlates of response and outcomes with talimogene laherperpvec.
Alice Y Zhou, Daniel Y Wang, Svetlana McKee, Fei Ye, Chun-Che Wen, Robert M Conry

J Surg Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients.
Brian C Westbrook, T Graham Norwood, Nina L J Terry, Svetlana B McKee, Robert M Conry

JAAD Case Rep· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.
Ines Pires da Silva, Isabella C Glitza, Lauren E Haydu, Romany Johnpulle, Patricia D Banks, Robert M Conry

Pigment Cell Melanoma Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1).
Matthew C Perez, Jonathan S Zager, Thomas Amatruda, Robert Conry, Charlotte Ariyan

Melanoma Manag· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma.
Ahmad A Tarhini, Sandra J Lee, Xiaoxue Li, Uma N M Rao, Arun Nagarajan, Robert M Conry

Clin Cancer Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib for Advanced and Refractory Desmoid Tumors.
Mrinal M Gounder, Michelle R Mahoney, Brian A Van Tine, Vinod Ravi, Steven Attia, Robert M Conry

N Engl J Med· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
Douglas B Johnson, Jennifer Bordeaux, Ju Young Kim, Christine Vaupel, David L Rimm, Robert M Conry

Clin Cancer Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characterization of colitis arising from anti-PD-1 based therapy.
Daniel Y Wang, Meghan J Mooradian, DaeWon Kim, Neil J Shah, Sarah E Fenton, Robert M Conry

Oncoimmunology· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Malignant Ewing-Like Neoplasm With an EWSR1-KLF15 Fusion: At the Crossroads of a Myoepithelial Carcinoma and a Ewing-Like Sarcoma. A Case Report With Treatment Options.
Todd M Stevens, Morad Qarmali, Diana Morlote, Fady M Mikhail, Jeffrey Swensen, Robert M Conry

Int J Surg Pathol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Brigitte Dreno, John F Thompson, Bernard Mark Smithers, Mario Santinami, Thomas Jouary, Robert Conry

Lancet Oncol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talimogene laherparepvec: First in class oncolytic virotherapy.
Robert M Conry, Brian Westbrook, Svetlana McKee, Timothy Graham Norwood

Hum Vaccin Immunother· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute inflammatory thyromegaly following checkpoint inhibition: A new imaging entity?
Erik H Middlebrooks, Brian C Westbrook, Robert M Conry

Radiol Case Rep· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.
Ashlyn S Everett, Peter G Pavlidakey, Carlo M Contreras, Jennifer F De Los Santos, Ju Y Kim, Robert M Conry

J Cutan Pathol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smoldering myocarditis following immune checkpoint blockade.
Timothy G Norwood, Brian C Westbrook, Douglas B Johnson, Silvio H Litovsky, Nina L Terry, Robert M Conry

J Immunother Cancer· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec.
Jonathan T Blackmon, Michael S Stratton, Young Kwak, Peter G Pavlidakey, Andrzej T Slominski, Robert M Conry

JAAD Case Rep· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy.
Samuel Marcrom, Jennifer F De Los Santos, Robert M Conry

Clin Sarcoma Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis